United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary ENDOLOGIX REPORTS 2005 FIRST QUARTER RESULTS
Irvine, Calif. – April 25, 2005 – Endologix, Inc. (Nasdaq: ELGX), developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment for abdominal aortic aneurysms (AAA), today announced financial results for the quarter ended
View HTML
Toggle Summary ENDOLOGIX REPORTS 2004 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
ENDOLOGIX REPORTS 2004 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS IRVINE, Calif. (March 14, 2005) Endologix, Inc. (NASDAQ: ELGX) , developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment for abdominal aortic aneurysms (AAA),
View HTML
Toggle Summary ENDOLOGIX TO PRESENT AT WELLS FARGO SECURITIES HEALTHCARE CONFERENCE
Webcast Scheduled March 1 at 10:30 p.m. ET
View HTML
Toggle Summary ENDOLOGIX APPOINTS HERBERT H. MERTENS VICE PRESIDENT OF SALES AND MARKETING
ENDOLOGIX APPOINTS HERBERT H. MERTENS VICE PRESIDENT OF SALES AND MARKETING IRVINE, Calif. (February 1, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced the appointment of Herbert H. Mertens to the newly created position of vice president of sales and marketing. He will oversee the U.S.
View HTML
Toggle Summary ENDOLOGIX NAMES RONALD H. COELYN TO BOARD OF DIRECTORS
ENDOLOGIX NAMES RONALD H. COELYN TO BOARD OF DIRECTORS IRVINE, Calif. (January 28, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that Ronald H. Coelyn has been appointed to its board of directors as an independent director, bringing Endologix board membership to eight.
View HTML
Toggle Summary ENDOLOGIX PRESENTS CLINICAL DATA AT INTERNATIONAL SYMPOSIUM OF ENDOVASCULAR THERAPY
Three-Year Preliminary Data Analysis Following Powerlink® Procedure Suggests Decreases in Aneurysm Sac Diameter and Volume
View HTML
Toggle Summary CRYOLIFE AND ENDOLOGIX SIGN DEVELOPMENT AGREEMENT FOR BIOFOAM
Endologix to develop CryoLife’s innovative, self-expanding sealant as a filling agent for aortic aneurysms
View HTML
Toggle Summary ENDOLOGIX REPORTS THIRD QUARTER RESULTS
ENDOLOGIX REPORTS THIRD QUARTER RESULTS Irvine, Calif. (November 9, 2004) Endologix, Inc., (NASDAQ: ELGX) today announced financial results for the quarter ended September 30, 2004. “We are exceptionally pleased to receive conditional U.S. marketing approval for our Powerlink® System
View HTML
Toggle Summary ENDOLOGIX RECEIVES FDA CONDITIONAL APPROVAL LETTER FOR Powerlink SYSTEM
- Company to Initiate Focused U.S. Market Launch -
View HTML
Toggle Summary Endologix Announces Special Meeting of Stockholders
Endologix Announces Special Meeting of Stockholders IRVINE, Calif. (November 1, 2004) Endologix, Inc. (Nasdaq: ELGX) today announced that it will hold a special meeting of stockholders on January 11, 2005 for the purpose of approving a 2,000,000 share increase in authorized shares under its 1996
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES TCT 2004 EVENTS
Live Powerlink System Surgical Procedure and Favorable Follow-on Clinical Data Presented
View HTML
Toggle Summary ENDOLOGIX NAMES ROBERT J. KRIST CHIEF FINANCIAL OFFICER
ENDOLOGIX NAMES ROBERT J. KRIST CHIEF FINANCIAL OFFICER IRVINE, Calif. (August 11, 2004) - Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that Robert J.
View HTML
Toggle Summary ENDOLOGIX TO PRESENT AT PACIFIC GROWTH EQUITIES LIFE SCIENCES GROWTH CONFERENCE
Webcast Scheduled June 9 at 5:00 p.m. ET
View HTML
Toggle Summary ENDOLOGIX, INC. REPORTS 2004 FIRST QUARTER RESULTS
ENDOLOGIX, INC. REPORTS 2004 FIRST QUARTER RESULTS Irvine, Calif. – May 10, 2004 – Endologix, Inc., (Nasdaq: ELGX), developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment for abdominal aortic aneurysms (AAAs), today
View HTML
Toggle Summary ENDOLOGIX PROVIDES DETAILS OF Powerlink® SYSTEM PIVOTAL TRIAL AT ANNUAL MEETING OF THE EASTERN VASCULAR SOCIETY
97.9% Device Deployment Success, 31% Treated with Regional or Local Anesthesia
View HTML